Filing identity and reporting period
Important mismatch: The request identifies Opus Genetics, Inc., but the supplied filing is Rexahn Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2015, filed March 14, 2016. The summary below covers the supplied Rexahn filing; it does not provide Opus Genetics financial information.
Rexahn was a clinical-stage oncology biopharmaceutical company with no approved products or product revenue. Its pipeline included Archexin in Phase II, RX-3117 and Supinoxin in Phase I, and RX-21101 in preclinical development.
Financial performance and position
| Metric | 2015 | 2014 | Change or context |
|---|---|---|---|
| Revenue | $0 | $0 | No product sales |
| Research and development expense | $12.15 million | $7.02 million | Up 73.2%, reflecting advancement of clinical programs |
| General and administrative expense | $6.12 million | $6.25 million | Down 2.2% |
| Total operating expenses | $18.26 million | $13.27 million | Up 37.7% |
| Net loss | $14.38 million | $18.52 million | Loss narrowed, largely reflecting a favorable noncash warrant valuation change |
| Net loss per share | $0.08 | $0.11 | Basic and diluted |
| Cash used in operating activities | $17.35 million | $11.04 million | Higher cash burn as development spending increased |
At year-end 2015, cash, cash equivalents and marketable securities totaled $23.44 million, down from $32.70 million. Working capital was $22.00 million, total assets $24.81 million, and stockholders’ equity $18.78 million. Current liabilities were $6.03 million, including $2.74 million of warrant liabilities. The filing does not show conventional borrowings in the balance sheet presented. No operating margin is meaningful because the company had no revenue.
The $3.99 million unrealized gain on warrant fair value materially reduced the reported 2015 net loss; it was noncash and followed a $5.18 million unrealized warrant loss in 2014. Warrant liabilities are valued using a model with significant assumptions.
Material changes and financing
- R&D spending rose substantially, especially for RX-3117 and Supinoxin; 2015 program costs were approximately $4.06 million and $2.84 million, respectively, versus $1.90 million and $1.35 million in 2014.
- Financing provided $8.17 million of net cash in 2015, primarily through equity issuance. In November 2015, Rexahn raised $7.0 million gross in a registered direct offering, issuing 16.67 million shares and warrants for up to 12.5 million shares.
- Common shares outstanding increased from 178.25 million at year-end 2014 to 197.41 million at year-end 2015. The 2015 offering and outstanding warrants create potential dilution.
- After year-end, on March 2, 2016, Rexahn raised a further $5.0 million gross by issuing 15.625 million shares and warrants for up to 11.719 million shares. The filing also reports 213,113,785 shares outstanding as of March 11, 2016.
Outlook, commentary, and risks
- Management said year-end cash, cash equivalents and marketable securities were expected to fund current activities for at least the next 12 months. The company nevertheless expected continued losses and said further capital would be needed to continue development; financing may be unavailable or dilutive.
- For 2016, Rexahn expected Archexin, RX-3117 and Supinoxin expenses to increase slightly as trials advanced, while preclinical pipeline spending was expected to remain flat. These are expectations, not guaranteed results.
- Archexin’s RCC Phase IIa trial began its expansion stage after dose-ranging; the selected dose was 250 mg/m²/day with everolimus. The completed pancreatic cancer Phase IIa study reported median survival of 9.1 months among evaluable patients, compared with historical single-agent gemcitabine data of 5.7 months; this was not a randomized comparison.
- Preliminary Phase Ib RX-3117 results reported one patient with tumor reduction and five with stable disease. Preliminary Supinoxin Phase I results reported stable disease in four patients for 255–497 days as of September 14, 2015. These early findings do not establish efficacy or approval prospects.
- Key risks include clinical and regulatory failure or delay, reliance on third-party research organizations and manufacturers, lack of commercial infrastructure, competition, uncertain intellectual-property protection, reimbursement and pricing constraints, and continuing capital needs. A Japanese patent application dispute concerning Supinoxin remained pending in court.
- Contractual commitments included $951,296 in future operating lease payments and approximately $9.38 million estimated to complete research and development vendor agreements, which were terminable on notice. Additional milestone payments under licenses may become due if specified development or approval events occur.
The financial statements received an unqualified audit opinion, and management and the auditor concluded internal control over financial reporting was effective as of December 31, 2015. The filing reported no legal proceedings and no off-balance-sheet arrangements.
Most important facts for investors to verify
- Confirm the intended issuer: the supplied document is Rexahn Pharmaceuticals, Inc., not Opus Genetics, Inc.
- Review audited statements and cash-burn assumptions underlying management’s estimate of at least 12 months of runway, including the effect of the March 2016 financing.
- Check subsequent share counts, outstanding warrants and exercise terms to assess dilution and potential warrant-liability volatility.
- Review trial status and complete clinical data; distinguish preliminary, uncontrolled observations and historical comparisons from confirmatory evidence.
- Assess whether the company can obtain additional financing or partnerships and meet development costs, vendor commitments and potential license milestones.